Bone Healing and Failure - Engineered Bone: Tissue Engineering Intelligence Unit - page 57

56. Wozney JM, Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family
in bone formation and repair. Clin Orthop 1998; 346:26-37.
57. Bostrom MP, Lane JM, Tomin E et al. Use of bone morphogenetic protein in the rabbit ulnar
nonunion model. Clin Orthop 1996; 327:272-82.
58. Yasko AW, Lane JM, Fellinger EJ et al. The healing of segmental bone defects, induced by recom-
binant human bone morphogenetic protein (rhBMP-2): A radiographic, histological, and biome-
chanical study in rats. J Bone Joint Surg 1992; 74A:659-670.
59. Cook SD, Baffes GC, Wolfe MW et al. The effect of recombinant human bone morphogenetic
protein-1 on healing large segmental bone defects. J Bone Joint Surg 1994; 76A:827-838.
60. Cook SD, Wolfe MW, Salked SL et al. Effect of recombinant human osteogenic protein-1 on
healing of segmental defects in nonhuman primates. J Bone Joint Surg 1995; 77A:734-750.
61. Cook SD, Baffes GC, Wolfe MW et al. Recombinant human bone morphogenetic protein-7 in-
duces healing in a canine long-bone segmental defect. Clin Orthop 1994; 301:302-12.
62. Sciandini MF, Dawson JM, Berman LM et al. Dose-response characteristics of recombinant hu-
man bone morphogenetic protein-2 (rhBMP-2) in a canine segmental defect model. Trans Orthop
Res Soc 1996; 41:284.
63. Zdeblick TA, Ghanayem AJ, Rapoff AJ et al. Cervical interbody fusion cages. An animal model
with and without bone morphogenetic protein. Spine 1998; 23:758-65.
64. Cook SD, Dalton JE, Tan EH et al. In vivo evaluation of recombinant human osteogenic protein
(rhOP-1) implants as bone graft substitute for spinal fusions. Spine 1994; 19:1655-1663.
65. Sandhu, Kanim LE, Kabo JM et al. Evaluation of rhBMP-2 with an OPLA carrier in canine pos-
terolateral (transverse process) spinal fusion model. Spine 1995; 20:2669-2682.
66. Sandhu HS, Kanim LE, Kabo JM et al. Effective doses of recombinant human bone morphoge-
netic protein-2 in experimental spinal fusion. Spine 1996; 21:2115-22.
67. Boden SD, Schimandle JH, Hutton WC et al. The use of an osteoinductive growth factor for
lumbar spinal fusion: Part I. Biology of spinal fusion. Spine 1995; 20:2626-2632.
68. Boden SD, Schimandle JH, Hutton WC et al. The use of an osteoinductive growth factor for
lumbar spinal fusion: Part II. Study of dose, carrier, and species. Spine 1995; 20:2633-2644.
69. Muschler GF, Hyodo A, Manning T et al. Evaluation of human bone morphogenetic protein 2 in
a canine spinal fusion model. Clin Orthop 1994; 308:229-240.
70. Fischgrund JS, James SB, Chabot MC et al. Augmentation of autograft using rhBMP-2 and differ-
ent carrier media in the canine spinal fusion model. J Spinal Disord 1997; 10:167-72.
71. Boden SD, Zdeblick TA, Sandhu HS et al. Definitive evidence of osteoinduction in humans: A
preliminary report. Spine 2000; 25(3):376-381.
72. Friedlaender GF, Perry CR, Cole JD et al. Osteogenic protein-1 (bone morphogenetic protein-7)
in the treatment of tibial nonunions. J Bone Joint Surg 2001; 83-A(S1):151-158.
73. Geesink RGT, Hoefnagels NHM, Bulstra SK. Osteogenic activity of OP-1, bone morphogenetic
protein-7 (BMP-7), in a human fibular defect model. J Bone Joint Surg 1999; 81-B:710-718.
74. Kleeman TJ, Ahn UM, Talbot-Kleeman A. Laparoscopic anterior lumbar interbody fusion with
rhBMP-2. A prospective study of clinical an radiographic outcomes. Spine 2001; 26(24):2751-2756.
75. Patel TC, Vaccaro AR, Truumees E et al. A safety and efficacy study of OP-1 (rhBMP-7) as an
adjunct to posterolateral lumbar fusion. Abstract - Proceedings of the North American Spine Soci-
ety; 15th Annual Meeting. New Orleans, Louisiana: 2000.
76. Patel TC, Vaccaro AR, Truumees E et al. Two year follow-up on a safety and efficacy study of
OP-1 (rhBMP-7) as an adjunct to posterolateral lumbar fusion. Abstract - Proceedings of the
North American Spine Society; 16th Annual Meeting. Seattle, Washington: 2001.
77. Bostrom MPG, Lane JM, Berberian WS et al. Immunolocalization and expression of bone mor-
phogenetic proteins 2 and 4 in fracture healing. J Orthop Res 1995; 13:357-367.
78. Chen D, Harris MA, Rossini G et al. Bone morphogenetic protein 2 (BMP-2)enhances BMP-3,
BMP-4 and bone cell differentiation marker gene expression during the induction of mineralized
bone matrix formation in culture of rat calvarial osteoblasts. Calcif Tissue Int 1997; 60:283-290.
79. Wozney JM, Rosen V, Celeste AJ et al. Novel regulators of bone formation: Molecular clones and
activities. Science 1988; 242:1528-1534.
80. Vukicevic S, Luyten FP, Reddi AH. Stimulation of the expression of osteogenic and chondrogenic
phenotypes in vitro by osteogenin. Proc Natl Acad Sci USA 1989; 86:8793-8797.
81. Amedee J, Bareille R, Rouais F et al. Osteogenin (bone morphogenetic protein 3) inhibits prolif-
eration and stimulates differentiation of osteoprogenitors in human bone marrow. Differentiation
1994; 58:157-164.
82. Carrington Jl, Chen P, Yanagishita M et al. Osteogenin (bone morphogenetic protein 3) stimulates
cartilage formation by chick limb bud cells in vitro. Dev Biol 1991; 146:406:415.